« Minn. Unions, Lawmakers Angered by Delay of Cancer Data
A new technology for cancer screening listens for the signs of cancer »

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

This study is currently recruiting participants.
Verified by National Cancer Institute (NCI) August 2007

Sponsors and Collaborators:

North Central Cancer Treatment GroupNational Cancer Institute (NCI)

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00459862


Purpose

RATIONALE: Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the tumor.

PURPOSE: This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant
pleural mesothelioma.











Condition

Intervention

Phase

Malignant Mesothelioma

 Drug: pazopanib hydrochloride
 Procedure: anti-cytokine therapy
 Procedure: antiangiogenesis therapy
 Procedure: biological markers
 Procedure: biological therapy
 Procedure: diagnostic test
 Procedure: enzyme inhibitor therapy
 Procedure: growth factor antagonist therapy
 Procedure: protein tyrosine kinase inhibitor therapy

 Phase II

MedlinePlus related topics:  Cancer;   Mesothelioma

Genetics Home Reference related topics:  Cancer

Study Type: Interventional
Study Design: Treatment, Open Label


Official Title: Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

  • Proportion of patients who are progression-free at 6 months

Secondary Outcome Measures:

  • Response to treatment

  • Overall survival

  • Progression-free survival

  • Duration of response

  • Time to treatment failure

  • Toxicity

  • Tumor markers of angiogenesis


Total Enrollment: 
55

Study start: March 2007

OBJECTIVES:

Primary

  • Determine the effect of pazopanib hydrochloride on the proportion of patients with malignant pleural mesothelioma who are
    progression-free at 6 months based on the RECIST criteria.

  • Determine the clinical toxicities of this drug in this patient population.

Secondary

  • Determine the objective tumor response status in these patients as measured by the RECIST criteria or the modified RECIST
    criteria.

  • Determine the response rate in patients treated with this drug.

  • Determine the effect of this drug on overall survival and time to progression in these patients.

  • Assess predictive markers of activity of this drug in these patients.

  • Assess serologic markers of target inhibition by this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the
absence of disease progression or unacceptable toxicity.

Blood is collected at baseline and prior to each course of therapy and analyzed for markers of angiogenesis.

After completion of study therapy, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.



Eligibility

Ages Eligible for Study: 
18 Years and above, 

Genders Eligible for Study: 
Both

Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed malignant pleural mesothelioma

    • Measurable disease

    • No progressive disease inside or outside of any prior radiation field

  • No symptomatic, untreated, or uncontrolled CNS metastases

    • Patients with CNS metastases treated with whole brain radiation (WBRT) may be enrolled after completion of WBRT

      • Patients may begin study therapy as early as the next day after completion of WBRT

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2

  • Life expectancy ≥ 12 weeks

  • ANC ≥1,500/mm³

  • Platelet count ≥ 100,000/mm³

  • WBC ≥ 3,000/mm³

  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)

  • AST and ALT ≤ 2.5 times ULN

  • Alkaline phosphatase ≤ 2.5 times ULN

  • Creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 mL/min

  • Proteinuria ≤ 1+ on 2 consecutive dipsticks taken ≥ 1 week apart

  • PT/INR/PTT ≤ 1.2 times ULN

  • Not pregnant or nursing

  • Negative pregnancy test

  • Fertile patients must use effective nonhormonal contraception

  • No uncontrolled infection

  • No uncontrolled blood pressure (BP) (defined as systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg in spite of adequate
    anti-hypertensive therapy)

  • No condition that impairs ability to swallow and retain study drug tablets including, but not limited to, any of the following:

    • Gastrointestinal tract disease resulting in an inability to take oral medication

    • Requirement for IV alimentation

    • Prior surgical procedures affecting absorption

    • Active peptic ulcer disease

  • No other severe underlying disease that, in the judgment of the investigator, would limit study compliance

  • No other primary malignancy except for carcinoma in situ of the cervix or nonmelanomatous skin cancer, unless that prior malignancy
    was diagnosed and definitively treated ≥ 5 years ago with no subsequent evidence of recurrence

    • Patients with a history of low-grade (Gleason score ≤ 6) localized prostate cancer are eligible even if diagnosed within the
      past 5 years

  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride
    or other agents used in the study

  • None of the following concurrent severe and/or uncontrolled medical conditions:

    • Serious or nonhealing wound, ulcer, or bone fracture

    • Abdominal fistula, diverticulosis, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

    • Poorly controlled diabetes

    • Interstitial pneumonia

    • Extensive and symptomatic interstitial fibrosis of the lung

  • No cardiovascular illness or complication, including any of the following:

    • Any history of cerebrovascular accident within the past 6 months

    • History of myocardial infarction (prior electrocardiographic evidence of myocardial injury)

    • History of cardiac arrhythmia (prior electrocardiographic evidence of abnormal heart rhythm)

    • Admission for unstable angina

    • Cardiac angioplasty or stenting within the past 12 months

    • NYHA class III-IV heart failure

      • Asymptomatic NYHA class II heart failure allowed

    • QTc prolongation (defined as a QTc interval ≥ 500 msecs) or other significant electrocardiogram abnormalities

    • Venous thrombosis within the past 12 weeks

  • No symptomatic, untreated, or uncontrolled seizure disorder

  • No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social
    situations that would limit study compliance

  • No significant traumatic injury within the past 4 weeks

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics

  • No more than 1 prior systemic therapy for malignant pleural mesothelioma

  • No ancillary therapy considered investigational within the past 4 weeks

  • No major surgery (i.e., laparotomy) or open biopsy within the past 4 weeks*

  • No minor surgery within the past 2 weeks*

  • Prior palliative radiotherapy allowed

    • No prior palliative radiotherapy to the chest except for a maximum of 3 fractions of radiotherapy for superior vena cava syndrome

  • No concurrent therapeutic warfarin

    • Low molecular-weight heparin or prophylactic low-dose warfarin allowed

  • No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy

  • No concurrent medications that act through the CYP450 system

  • No concurrent combination antiretroviral therapy for HIV-positive patients NOTE: *Insertion of a vascular access device is
    not considered major or minor surgery



Location

and Contact

Information

Please refer to this study by ClinicalTrials.gov identifier 

NCT00459862


United States, Illinois
      BroMenn Regional Medical Center, Normal, 
Illinois, 
61761, 
United States; Recruiting
John W. Kugler, MD
 309-243-3000 

      Cancer Treatment Center at Pekin Hospital, Pekin, 
Illinois, 
61554, 
United States; Recruiting
, John W. Kugler, MD
 309-243-3000 

      Carle Cancer Center at Carle Foundation Hospital, Urbana, 

Illinois, 
61801, 
United States; Recruiting

Clinical Trials Office - Carle Cancer Center at Carle Foundati
 800-446-5532 


      CCOP - Carle Cancer Center, Urbana, 
Illinois, 

61801, 
United States; Recruiting

Clinical Trials Office - CCOP - Carle Cancer Center
 800-446-5532 


      CCOP - Illinois Oncology Research Association, Peoria, 
Illinois, 
61615, 

United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Community Cancer Center, Normal, 
Illinois, 
61761, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 



      Community Hospital of Ottawa, Ottawa, 
Illinois, 
61350, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Eureka Community Hospital, Eureka, 

Illinois, 
61530, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Galesburg Clinic, PC, Galesburg, 
Illinois, 

61401, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Galesburg Cottage Hospital, Galesburg, 
Illinois, 
61401, 

United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Graham Hospital, Canton, 
Illinois, 
61520, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 



      Hopedale Medical Complex, Hopedale, 
Illinois, 
61747, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Illinois Valley Community Hospital, Peru, 

Illinois, 
61354, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Joliet Oncology-Hematology Associates, Limited - West, Joliet, 
Illinois, 

60435, 
United States; Recruiting

Kendrith M. Rowland, MD
 217-383-3010 


      Kewanee Hospital, Kewanee, 
Illinois, 
61443, 

United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Mason District Hospital, Havana, 
Illinois, 
62644, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 



      McDonough District Hospital, Macomb, 
Illinois, 
61455, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Memorial Hospital, Carthage, 

Illinois, 
62321, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Methodist Medical Center of Illinois, Peoria, 
Illinois, 

61636, 
United States; Recruiting

Clinical Trials Office - Methodist Medical Center of Illinois
 309-243-3000 


      Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, 
Illinois, 
61350, 

United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, 
Illinois, 
61615, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 



      OSF St. Francis Medical Center, Peoria, 
Illinois, 
61637, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Perry Memorial Hospital, Princeton, 

Illinois, 
61356, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Proctor Hospital, Peoria, 
Illinois, 

61614, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


      Rush-Copley Cancer Care Center, Aurora, 
Illinois, 
60507, 

United States; Recruiting

Kendrith M. Rowland, MD
 217-383-3010 


      St. Joseph Medical Center, Bloomington, 
Illinois, 
61701, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 



      St. Margaret’s Hospital, Spring Valley, 
Illinois, 
61362, 
United States; Recruiting

John W. Kugler, MD
 309-243-3000 


United States, Indiana
      Reid Hospital & Health Care Services, Richmond, 

Indiana, 
47374, 
United States; Recruiting

Howard M. Gross, MD
 765-983-3000 


      Saint Anthony Memorial Health Centers, Michigan City, 
Indiana, 

46360, 
United States; Recruiting

Kendrith M. Rowland, MD
 217-383-3010 


      St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, 
Indiana, 
46107, 

United States; Recruiting

Howard M. Gross, MD
 317-787-3311 


United States, Iowa
      CCOP - Iowa Oncology Research Association, Des Moines, 
Iowa, 
50309, 

United States; Recruiting

Roscoe F. Morton, MD, FACP
 515-244-7586 


      Cedar Rapids Oncology Associates, Cedar Rapids, 
Iowa, 
52403, 
United States; Recruiting

Clinical Trials Office - Cedar Rapids Oncology Associates
 319-363-2690 



      John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, 
Iowa, 
50316, 
United States; Recruiting

Clinical Trials Office - John Stoddard Cancer Center at Iowa L
 515-241-8704 


      John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, 

Iowa, 
50309, 
United States; Recruiting

Clinical Trials Office - John Stoddard Cancer Center at Iowa M
 515-241-6727 


      Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, 
Iowa, 

50309, 
United States; Recruiting

Roscoe F. Morton, MD, FACP
 515-244-7586 


      Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, 
Iowa, 
50314, 

United States; Recruiting

Roscoe F. Morton, MD, FACP
 515-244-7586 


      Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, 
Iowa, 
50314, 
United States; Recruiting

Roscoe F. Morton, MD, FACP
 515-244-7586 



      Mercy Capitol Hospital, Des Moines, 
Iowa, 
50307, 
United States; Recruiting

Roscoe F. Morton, MD, FACP
 515-244-7586 


      Mercy Medical Center - Sioux City, Sioux City, 

Iowa, 
51104, 
United States; Recruiting

Donald B. Wender, MD, PhD
 712-252-9326 


      Siouxland Hematology-Oncology Associates, LLP, Sioux City, 
Iowa, 

51101, 
United States; Recruiting

Donald B. Wender, MD, PhD
 712-252-9326 


      St. Luke’s Regional Medical Center, Sioux City, 
Iowa, 
51104, 

United States; Recruiting

Donald B. Wender, MD, PhD
 712-252-9326 


United States, Kansas
      Associates in Womens Health, PA - North Review, Wichita, 
Kansas, 
67203, 

United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Kingman, Kingman, 
Kansas, 
67068, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 



      Cancer Center of Kansas, PA - Wichita, Wichita, 
Kansas, 
67214, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Chanute, Chanute, 

Kansas, 
66720, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Dodge City, Dodge City, 
Kansas, 

67801, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - El Dorado, El Dorado, 
Kansas, 
67042, 

United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, 
Kansas, 
67208, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 



      Cancer Center of Kansas, PA - Newton, Newton, 
Kansas, 
67114, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Parsons, Parsons, 

Kansas, 
67357, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Pratt, Pratt, 
Kansas, 

67124, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Salina, Salina, 
Kansas, 
67042, 

United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Cancer Center of Kansas, PA - Wellington, Wellington, 
Kansas, 
67152, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 



      Cancer Center of Kansas, PA - Winfield, Winfield, 
Kansas, 
67156, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      CCOP - Wichita, Wichita, 

Kansas, 
67214, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Southwest Medical Center, Liberal, 
Kansas, 

67901, 
United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


      Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, 
Kansas, 
67214, 

United States; Recruiting

Shaker R. Dakhil, MD, FACP
 316-262-4467 


United States, Michigan
      Dickinson County Healthcare System, Iron Mountain, 
Michigan, 
49801, 

United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 


      Green Bay Oncology, Limited - Escanaba, Escanaba, 
Michigan, 
49431, 
United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 



United States, Minnesota
      CCOP - Metro-Minnesota, Saint Louis Park, 
Minnesota, 
55416, 
United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 



      Fairview Ridges Hospital, Burnsville, 
Minnesota, 
55337, 
United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 


      Fairview Southdale Hospital, Edina, 

Minnesota, 
55435, 
United States; Recruiting

Clinical Trials Office - Fairview Southdale Hospital
 612-625-3650 


      HealthEast Cancer Care at St. John’s Hospital, Maplewood, 
Minnesota, 

55109, 
United States; Recruiting

Daniel M. Anderson
 651-232-7970 


      HealthEast Cancer Care at St. Joseph’s Hospital, St Paul, 
Minnesota, 
55102, 

United States; Recruiting

Daniel M. Anderson
 651-232-7970 


      HealthEast Cancer Care at Woodwinds Health Campus, Woodbury, 
Minnesota, 
55125, 
United States; Recruiting

Daniel M. Anderson
 651-232-7970 



      Hennepin County Medical Center - Minneapolis, Minneapolis, 
Minnesota, 
55415, 
United States; Recruiting

Clinical Trials Office - Hennepin County Medical Center - Minn
 612-873-5911 


      Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, 

Minnesota, 
55422-2900, 
United States; Recruiting

Clinical Trials Office - Hubert H. Humphrey Cancer Center at N
 763-520-1893 


      Hutchinson Area Health Care, Hutchinson, 
Minnesota, 

55350, 
United States; Recruiting

Daniel M. Anderson
 320-234-5000 


      Mayo Clinic Cancer Center, Rochester, 
Minnesota, 
55905, 

United States; Recruiting

Clinical Trials Office - Mayo Clinic Cancer Center
 507-538-7623 


      Meeker County Memorial Hospital, Lichfield, 
Minnesota, 
55355, 
United States; Recruiting

Clinical Trials Office - Meeker County Memorial Hospital
 320-693-4520 



      Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, 
Minnesota, 
55433, 
United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 


      Mercy and Unity Cancer Center at Unity Hospital, Fridley, 

Minnesota, 
55432, 
United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 


      Minnesota Oncology Hematology, PA - Maplewood, Maplewood, 
Minnesota, 

55109, 
United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 


      Minnesota Oncology Hematology, PA - Woodbury, Woodbury, 
Minnesota, 
55125, 

United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 


      Park Nicollet Cancer Center, St. Louis Park, 
Minnesota, 
55416, 
United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 



      Regions Hospital Cancer Care Center, St. Paul, 
Minnesota, 
55101, 
United States; Recruiting

Clinical Trials Office - Regions Hospital Cancer Care Center
 651-254-1517 


      Ridgeview Medical Center, Waconia, 

Minnesota, 
55387, 
United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 


      St. Francis Cancer Center at St. Francis Medical Center, Shakopee, 
Minnesota, 

55379, 
United States; Recruiting

Daniel M. Anderson
 952-403-2031 


      United Hospital, St. Paul, 
Minnesota, 
55102, 

United States; Recruiting

Patrick J. Flynn, MD
 612-863-8585 


      Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, 
Minnesota, 
55407, 
United States; Recruiting

Clinical Trials Office - Virginia Piper Cancer Institute
 612-863-5654 



United States, Montana
      Billings Clinic - Downtown, Billings, 
Montana, 
59107-7000, 
United States; Recruiting

Clinical Trials Office - Billings Clinic - Downtown
 800-996-2663 

 
research@billingsclinic.org 


      Bozeman Deaconess Cancer Center, Bozeman, 
Montana, 
59715, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-585-5000 



      CCOP - Montana Cancer Consortium, Billings, 
Montana, 
59101, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-259-2245 


      Community Medical Center, Missoula, 

Montana, 
59801, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-728-4100 


      Glacier Oncology, PLLC, Kalispell, 
Montana, 

59901, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-752-7600 


      Great Falls Clinic - Main Facility, Great Falls, 
Montana, 
59405, 

United States; Recruiting

Benjamin T. Marchello, MD
 406-454-2171 


      Guardian Oncology and Center for Wellness, Missoula, 
Montana, 
59804, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-721-1118 



      Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, 
Montana, 
59101, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-238-6290 


      Kalispell Medical Oncology at KRMC, Kalispell, 

Montana, 
59901, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-752-8900 


      Kalispell Regional Medical Center, Kalispell, 
Montana, 

59901, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-752-5111 


      Great Falls, 
Montana, 
59405, 

United States; Recruiting

Benjamin T. Marchello, MD

      Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, 
Montana, 
59807, 
United States; Recruiting

Clinical Trials Office - Montana Cancer Center at St. Patrick
 406-329-7029 



      Montana Cancer Specialists at Montana Cancer Center, Missoula, 
Montana, 
59807-7877, 
United States; Recruiting

Clinical Trials Office - Montana Cancer Specialists at Montana
 406-238-6962 


      Northern Rockies Radiation Oncology Center, Billings, 

Montana, 
59101, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-248-2212 


      St. James Healthcare Cancer Care, Butte, 
Montana, 

59701, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-723-2500 


      St. Peter’s Hospital, Helena, 
Montana, 
59601, 

United States; Recruiting

Benjamin T. Marchello, MD
 406-442-2480 


      St. Vincent Healthcare Cancer Care Services, Billings, 
Montana, 
59101, 
United States; Recruiting

Benjamin T. Marchello, MD
 406-657-7000 



United States, Nebraska
      Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, 
Nebraska, 
68124, 
United States; Recruiting

Clinical Trials Office - Alegant Health Cancer Center at Berge
 402-398-6060 



      CCOP - Missouri Valley Cancer Consortium, Omaha, 
Nebraska, 
68106, 
United States; Recruiting

Gamini S. Soori, MD, FACP, FRCP, MBA
 402-393-3110 


      Creighton University Medical Center, Omaha, 

Nebraska, 
68131-2197, 
United States; Recruiting

Clinical Trials Office - Creighton University Medical Center
 402-280-4100 


      Immanuel Medical Center, Omaha, 
Nebraska, 

68122, 
United States; Recruiting

Gamini S. Soori, MD, FACP, FRCP, MBA
 402-393-3110 


United States, North Carolina
      Rutherford Hospital, Rutherfordton, 
North Carolina, 

28139, 
United States; Recruiting

James D. Bearden, MD
 864-560-6812 


United States, North Dakota
      Bismarck Cancer Center, Bismarck, 
North Dakota, 

58501, 
United States; Recruiting

Edward J. Wos, DO
 701-323-5741 


      Medcenter One Hospital Cancer Care Center, Bismarck, 
North Dakota, 
58501, 

United States; Recruiting

Edward J. Wos, DO
 701-323-5741 


      Mid Dakota Clinic, PC, Bismarck, 
North Dakota, 
58501, 
United States; Recruiting

Clinical Trials Office - Mid Dakota Clinic, PC
 701-530-6950 



      St. Alexius Medical Center Cancer Center, Bismarck, 
North Dakota, 
58502, 
United States; Recruiting

Clinical Trials Office - St. Alexius Medical Center Cancer Cen
 701-530-6950 


United States, Ohio
      Blanchard Valley Medical Associates, Findlay, 

Ohio, 
45840, 
United States; Recruiting

Howard M. Gross, MD
 419-424-0380 


      CCOP - Dayton, Dayton, 
Ohio, 

45429, 
United States; Recruiting

Howard M. Gross, MD
 937-395-8678 


      Charles F. Kettering Memorial Hospital, Kettering, 
Ohio, 
45429, 

United States; Recruiting

Clinical Trials Office - Charles F. Kettering Memorial Hospita
 937-298-3399 ext. 58868 


      David L. Rike Cancer Center at Miami Valley Hospital, Dayton, 
Ohio, 
45409, 
United States; Recruiting

Clinical Trials Office - David L. Rike Cancer Center at Miami
 937-208-2079 



      Good Samaritan Hospital, Dayton, 
Ohio, 
45406, 
United States; Recruiting

Howard M. Gross, MD
 937-278-2612 


      Grandview Hospital, Dayton, 

Ohio, 
45405, 
United States; Recruiting

Howard M. Gross, MD
 937-226-3200 


      Middletown Regional Hospital, Middletown, 
Ohio, 

45044, 
United States; Recruiting

Howard M. Gross, MD
 513-424-2111 


      Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, 
Ohio, 
45385, 

United States; Recruiting

Howard M. Gross, MD
 937-352-2140 


      Samaritan North Cancer Care Center, Dayton, 
Ohio, 
45415, 
United States; Recruiting

Howard M. Gross, MD
 937-279-5800 



      UVMC Cancer Care Center at Upper Valley Medical Center, Troy, 
Ohio, 
45373-1300, 
United States; Recruiting

Clinical Trials Office - UVMC Cancer Care Center at Upper Vall
 937-440-4842 


      Veterans Affairs Medical Center - Dayton, Dayton, 

Ohio, 
45428, 
United States; Recruiting

Howard M. Gross, MD
 937-268-6511 


United States, Pennsylvania
      Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, 

Pennsylvania, 
18105, 
United States; Recruiting

Suresh G. Nair, MD
 610-402-0500 


United States, South Carolina
      AnMed Cancer Center, Anderson, 

South Carolina, 
29621, 
United States; Recruiting

Clinical Trials Office - AnMed Cancer Center
 864-512-1000 


      CCOP - Upstate Carolina, Spartanburg, 
South Carolina, 

29303, 
United States; Recruiting

Clinical Trials Office - CCOP - Upstate Carolina
 800-486-5941 


      Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, 
South Carolina, 
29303, 

United States; Recruiting

Clinical Trials Office - Gibbs Regional Cancer Center at Spart
 800-486-5941 


United States, South Dakota
      Rapid City Regional Hospital, Rapid City, 
South Dakota, 
57701, 

United States; Recruiting

Richard C. Tenglin
 605-719-2360 


United States, Wisconsin
      Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, 
Wisconsin, 
54143, 

United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 


      Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, 
Wisconsin, 
54154, 
United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 



      Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, 
Wisconsin, 
54235, 
United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 


      Green Bay Oncology, Limited at St. Mary’s Hospital, Green Bay, 

Wisconsin, 
54303, 
United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 


      Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, 
Wisconsin, 

54301-3526, 
United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 


      St. Mary’s Hospital Medical Center - Green Bay, Green Bay, 
Wisconsin, 
54303, 

United States; Recruiting

Anthony J. Jaslowski, MD, FACP
 920-884-3135 


      St. Vincent Hospital Regional Cancer Center, Green Bay, 
Wisconsin, 
54307-3508, 
United States; Recruiting

Clinical Trials Office - St. Vincent Hospital Regional Cancer
 920-433-8889 



United States, Wyoming
      Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, 
Wyoming, 
82801, 
United States; Recruiting

Benjamin T. Marchello, MD
 307-674-6022 




Study chairs or principal investigators

Julian Molina, MD, PhD,  Study Chair,  Mayo Clinic
  
Nicholas F. Reuter, MD,  Coborn Cancer Center
  

More Information


Clinical trial summary from the National Cancer Institute’s
PDQ® database

Study ID Numbers: 
CDR0000539269; NCCTG-N0623

Last Updated: 

September 5, 2007

Record first received: 
April 11, 2007

ClinicalTrials.gov Identifier: 
NCT00459862
Health Authority: Unspecified

ClinicalTrials.gov processed this record on September 20, 2007

Source: www.ClinicalTrials.gov

This entry was posted on Friday, September 21st, 2007 @ 10:04 am on the category Mesothelioma Treatments.You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback from your own site.

Leave a reply